Predict your next investment

MOBILE & TELECOMMUNICATIONS | Mobile Software & Services / Healthcare

See what CB Insights has to offer


Acquired | Acquired

About WellApps

WellApps is a mobile health company that develops disease management applications for patients with chronic illnesses. WellApps application GI Monitor is a mobile disease-management platform for patients with Inflammatory Bowel Disease (IBD), Crohn's Disease and Ulcerative Colitis. The app allows patients to easily and accurately log symptoms and provide this data to their doctors for optimal treatment. In addition, patients can see correlations between symptoms, meals and medications.In March 2012, WellApps was acquired by Medivo. The valuation of WellApps was undisclosed. Other terms of the deal were not released.

WellApps Headquarter Location

New York, New York,

United States

Latest WellApps News

Medivo Leverages Mobile Strategy to Get Ahead in Health Information

Mar 20, 2012

Reprints With the world awash in health IT startups, New York’s Medivo is battling to prove it is different from other startups in this sector. So on March 7, the company—which operates a Web and mobile platform that connects doctors to their patients—acquired NYC neighbor WellApps, which creates mobile apps for monitoring symptoms of serious intestinal illnesses. The acquisition is part of Medivo’s overall mission to create a comprehensive electronic dashboard for physicians that provides real-time updates to doctors on their patients’ conditions. Medivo, founded in 2010, focuses on connecting patients with physicians in between visits. “It is very difficult for physicians to provide real care between visits,” says co-founder and CEO Sundeep Bhan, because patients typically do not contact doctors until something is wrong. Medivo’s platform is aimed at keeping both sides in touch more regularly. “This is like a customer-relationship management system that allows the doctor’s office to build and maintain a relationship that provides care to the patient in between visits,” he says. Medivo’s platform generates electronic reports for physicians and sends automated reminders to patients about follow-up care and tests that need to be performed. Medivo started with a Web-based platform but is now moving into mobile with the acquisition of WellApps. About 30,000 patients with conditions such as Crohn’s disease, inflammatory bowel disease, and ulcerative colitis use mobile apps from WellApps to record their symptoms, he says. By meshing WellApps’s technology with its own, Medivo also plans to offer mobile access to information and symptom tracking for other illnesses the company covers, according to Bhan. As the market for technology that connects patients and doctors gets increasingly crowded, Medivo will have to work hard to distinguish its services from those of its rivals. New York-based Hello Health, for example, recently pulled in $10 million to develop its own dashboard , which it is partly developing in collaboration with electronics giant Qualcomm. For Medivo to keep up, it may need to consider future acquisitions. Last November, the company raised $7 million in a Series A funding round led by Safeguard Scientifics . Medivo previously raised a seed round of $700,000 with such backers as MentorTech Ventures, the ARC Angel Fund, and angel investors including Esther Dyson. “We’re not a roll-up [operation] but if there are specific opportunities that can … Next Page » João-Pierre S. Ruth is the editor of Xconomy New York. He can be reached at and followed on Twitter @jpruth. Follow @jpruth

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.